The CiteScore of Journal of Cancer Metastasis and Treatment has Increased to 3.2 in 2022
On June 8th, Elsevier released the latest CiteScore. We are delighted to report that the 2022 CiteScore of Journal of Cancer Metastasis and Treatment(JCMT) has shown a significant increase. It has grown from 0.4 to 3.2. This substantial rise highlights the impactful and high-quality content published by JCMT in the field of oncology, reaffirming the journal's continuous progress.
CiteScore is a set of metrics that measure a scholarly journal’s impact by analyzing the average number of citations per item it received over a three-year period. It covers over 22,500 journals indexed in Scopus, Elsevier’s comprehensive citation database.
We would like to express our sincere appreciation to all the authors, Editorial Board Members, reviewers, and readers for their invaluable contribution and unwavering support, which collectively contribute to the journal’s achievement.
Here are some highly cited articles worth recommending:
- Seaweeds’ nutraceutical and biomedical potential in cancer therapy: A concise review
- Research progress on KRAS mutations in colorectal cancer
- Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma
- Bulbine frutescens phytochemicals as novel ABC-transporter inhibitor: a molecular docking and molecular dynamics simulation study
- The use of liquid biopsy in early breast cancer: Clinical evidence and future perspectives
- Chronic activation of MUC1-C in wound repair promotes progression to cancer stem cells
JCMT will continue publishing high-quality papers that advance and lead scientific developments in the field of oncology.